Antibodies to the envelope protein protect macaques from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai trial

• DOI: 10.1186/1742-4690-9-s2-o2
• Publication Date: 2012-09-13T06:16:17Z
• Authors: G Franchini; P Pegu; S Gordon; B Keele; M Doster; Y Guan; G Ferrari; R Pal; MG Ferrari; S Whitney; L Hudacik; E Billings; M Rao; D Montefiori; D Venzon; C Fenizia; J Lifson; D Stablein; J Tartaglia; N Michael; J Kim
• Keywords: Regimen; Envelope (radar)

Background The canarypox vector ALVAC-HIV, together with the HIV gp120 envelope, has protected 31.2% of Thai heterosexual individuals from acquisition in RV144 vaccine trial. This outcome was unexpected, given limited ability ALVAC-HIV component to induce CD8+T-cell responses, and HIVgp120 envelope elicit broad neutralizing antibodies. Methods We vaccinated macaques an immunization regimen that mimics trial exposed them a mucosal dose SIVmac251 transmits few virus variants, similar transmission humans. Results